0
Observation |

Peripheral Nerve Toxic Effects of Nitrofurantoin FREE

Ik Lin Tan, MBBS, FRACP; Michael J. Polydefkis, MD, MHS; Gigi J. Ebenezer, MBBS, MD; Peter Hauer, BS; Justin C. McArthur, MBBS, MD
[+] Author Affiliations

Author Affiliations: Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland.


Arch Neurol. 2012;69(2):265-268. doi:10.1001/archneurol.2011.1120.
Text Size: A A A
Published online

Objective To investigate the role of skin biopsy in nitrofurantoin peripheral neuropathy.

Design We describe the clinical features and skin biopsies of 2 cases of non–length-dependent small-fiber neuropathy/ganglionopathy attributable to nitrofurantoin.

Setting Clinical evaluation and skin biopsies were performed at a tertiary teaching hospital in Baltimore, Maryland.

Patients A 59-year-old woman with disabling generalized dysesthesia and a 53-year-old woman with progressive burning pain in the perineum and extremities.

Main Outcome Measures Slow or incomplete recovery and possibly irreversible damage.

Results The neuropathy was neither dose dependent nor associated with impaired renal function. Results from nerve conduction studies were normal. Skin biopsies revealed distinctive morphologic changes with clustered terminal nerve swellings without evidence of nerve fiber degeneration.

Conclusions These distinct morphologic changes associated with nitrofurantoin have not been previously reported to our knowledge. Skin biopsy appears to be helpful in confirming the diagnosis in these patients.

Figures in this Article

Nitrofurantoin is an antibiotic used mainly in the treatment of urinary tract infections. Nitrofurantoin neuropathy, predominantly a length-dependent sensorimotor neuropathy, has been described. We describe 2 patients with relatively short exposure to nitrofurantoin who developed non–length-dependent neuropathic pain. While clinical examination and conventional nerve conduction study findings were unremarkable, the results from skin biopsies were abnormal with distinctive morphologic changes. The unrelenting course of dysesthesias despite discontinuation of nitrofurantoin in the 2 patients may suggest irreversible damage.

CASE 1

A 59-year-old woman had a 2-year history of generalized patchy dysesthesias. Her medical history was significant only for interstitial cystitis. Two years prior, she had been treated with prophylactic nitrofurantoin, 100 mg daily, for urinary retention following the repair of a bladder prolapse. Four weeks into the therapy, she reported generalized dysesthesias with prickly heat and sunburnlike sensations, which were pronounced in the thighs, shoulders, and neck. She developed generalized livedo reticularis and photosensitivity across her face and extremities. Her symptoms persisted despite discontinuation of nitrofurantoin. The results from extensive investigations including autoimmune and connective tissue serology were unremarkable. A trial of high dose prednisolone acetate, 60 mg/d relieved her symptoms, but they recurred on prednisolone tapering. Treatment with antihistamine and leukotriene blockers had no effect on her symptoms. She was fatigued and lost 6.80 kg.

Neurologic examination revealed preserved muscle strength and tendon reflexes in all extremities. Sensory examination was intact to vibration, proprioception, light touch, and pin prick. Her gait was normal and her Romberg Test was negative. Results from a nerve conduction study (NCS) were unremarkable. Her skin biopsy showed normal intraepidermal nerve fiber density (INFD), with pronounced morphologic changes of clustered swellings of terminal nerve fibers.

Her neuropathic symptoms were managed with gabapentin and duloxetine hydrochloride, providing partial relief. At 3 years, she continued to be symptomatic.

CASE 2

A 53-year-old woman had a 6-month history of dysesthesias. Her medical history was significant for psoriasis treated with metrotrexate sodium. She was prescribed nitrofurantoin for 1 week for a urinary tract infection, after which she developed burning pelvic pain. Assuming recurrent urinary tract infections, she failed to respond to multiple trials of oral antibiotics. Laparoscopic examination found no cause for her pelvic pain. Her symptoms worsened to involve her hands, feet, shoulders, thighs, and perineum and were described as intense burning. She had flulike symptoms with malaise, headache, and arthralgia, and she lost 11.33 kg.

Physical examination revealed no lateralizing signs or motor deficits. She had intact sensation to light touch, temperature, vibration, and proprioception. Her Romberg Test was negative.

Results from extensive investigations including folate, vitamin B6, and vitamin B12 levels; methylmalonic acid levels; celiac serology; parvovirus B19 IgM; autoimmune serology (including Sjögren antibodies); Lyme serology; paraneoplastic screen; heavy metal screen; thyroid function test, and serum protein electrophoresis were all unremarkable. Cerebrospinal fluid examination revealed a glucose level of 55 mg/dL (to convert to millimoles per liter, multiply by 0.0555), protein level of 67 mg/dL, and white blood cell count of 1/μL (to convert to ×109 per liter, multiply by 0.001) with negative flow cytometry. Nerve conduction studies and electromyography results were normal, with a right sural amplitude of 40.8 μV and velocity of 40 m/s. A skin biopsy revealed INFD that was within the normal limits. There were morphologic abnormalities, with clustered terminal nerve fiber swellings (Figure).

Place holder to copy figure label and caption
Graphic Jump Location

Figure. Skin biopsy findings. A, Baseline skin biopsy specimen from the distal leg showing preserved epidermal fibers and clusters of abnormal axonal swellings in the dermis (arrows) that persisted after 6 months. Staining was done with panaxonal protein gene product 9.5 (ubiquitin hydrolase; ABD Serotec). B, The nerve fibers were immunostained with the panaxonal marker protein gene product 9.5. Scale bars indicate 50 μm.

She began treatment with duloxetine hydrochloride and transdermal fentanyl, with significant improvement of her symptoms allowing for resumption of work and exercise. Findings from repeated skin biopsy performed 6 months later were essentially unchanged, with persistent axonal swellings and normal INFD (Figure).

SKIN BIOPSY

Punch biopsies were performed with a 3-mm disposable circular punch (Acupunch; Acuderm) after the injection of lidocaine hydrochloride, 2%, under an aseptic technique. Biopsy specimens were obtained from the lateral aspect of the following sites: the upper thigh (10 cm below the greater trochanter), the distal thigh (10 cm above the patella), and at the ankle (10 cm above the lateral malleolus). Specimens were fixed in Zamboni solution, and free-floating 50-μm sections were immunostained with the panaxonal marker protein gene product 9.5 (ubiquitin hydrolase; ABD Serotec). For each biopsy, at least 3 sections were read. The epidermal fibers were identified, counted, and documented as the number of intraepidermal nerve fibers per millimeter of epidermis. The morphology of nerve fibers was observed. Technical details have previously been described.1

Nitrofurantoin was first introduced in 1952. It is a synthetic antimicrobial derived from furan by the addition of a nitro group and a side chain containing hydantoin.2 Its antibacterial spectrum is broad and is particularly effective against Escherichia coli and Klebsiella and Enterobacter species, hence its use for the treatment of urinary tract infections. Nitrofurantoin is excreted and concentrated in the urine. In the presence of impaired renal function, the urine levels fall below the therapeutic range while the serum levels increase into the toxic range.3 Thus, its efficacy is limited in the setting of renal impairment, with an associated greater risk of toxic effects and adverse reactions.

Nitrofurantoin is an overall relatively safe drug. Primary adverse effects are predominantly gastrointestinal tract symptoms with nausea, emesis, and anorexia. Peripheral neuropathy is a less-recognized adverse reaction. The first case of peripheral neuropathy attributable to nitrofurantoin was reported by de Fine Olivarius in 1956.4 Since then, many more cases and reviews have been published, although these were mainly reported in the 1960s through 1980s.57

Typically, nitrofurantoin neuropathy manifests as length-dependent sensorimotor polyneuropathy.5,6 The glove and stocking pattern of sensory symptoms were accompanied by varying degrees of motor weakness in the same pattern of distribution, with muscle atrophy of the intrinsic muscles in severe cases. Only 2 cases with perineum disturbance have been reported.6,7 Most patients had moderate to severe abnormal sensory and motor conduction on NCS and axonal degeneration on sural nerve biopsy.5

In contrast, our patients had non–length-dependent small-fiber neuropathy/ganglionopathy. The first patient presented with generalized body dysesthesias, while the second patient had predominantly perineum symptoms with subsequent involvement of the extremities. Their NCS and electromyography results were unremarkable, thus excluding large-fiber polyneuropathy. Skin biopsies revealed normal INFD but abnormal morphology, with clustered swelling of the nerve fibers. Both patients were female and in their 50s. The duration of the exposure and cumulative doses were relatively short: 4 weeks of a prophylactic dose in the first patient and only 1 week of a therapeutic dose in the second patient. Both patients had normal renal function. Despite discontinuation of nitrofurantoin, the symptoms progressed unabated. The first patient had persistent symptoms, albeit with some improvement, 3 years following discontinuation of nitrofurantoin.

Symmetric, non–length-dependent neuropathic pain involving proximal regions of the limbs, face, and trunk, either sparing the acral extremities or with simultaneous involvement of both proximal and distal extremities, suggests a selective disorder of the dorsal ganglia cells subserving small nerve fibers. The commonly implicated causes include glucose intolerance, Sjögren syndrome, paraproteinemia, celiac disease, hepatitis C, and paraneoplastic syndrome and are idiopathic in most cases.810 Our cases suggest that neurotoxic neuropathy must also be considered in the differential diagnoses.

Skin biopsy is a useful investigation to confirm the diagnosis of small-fiber neuropathy. Length-dependent small-fiber neuropathy demonstrates the typical proximal-distal gradient of INFD density, confirming the length-dependent loss of cutaneous innervation. Conversely, ganglionopathy or non–length-dependent small-fiber neuropathy in patients with hyperesthesias reveals a distinct pattern of epidermal denervation, with either normal INFDs on all sites or loss of INFD proximally but preservation distally.10

The morphologic changes of clustering of swelling of nerve fibers in the papillary dermis are most unusual. This morphologic feature is not unique to nitrofurantoin and has also been observed in ganglionopathy10 and small-fiber neuropathy secondary to Sjögren syndrome.11

The mechanisms for the predilection for the nerve fibers, in particular small-caliber fibers, in the papillary dermis are unknown. Nitrofurantoin interferes with pyruvate oxidation by competing with thiamine pyrophysphate.12 However, neurotoxic neuropathies from other causes (eg, vitamin B6 excess) are not associated with such nerve fiber changes on skin biopsy.

Although axonal swellings have been found to predict the degeneration of epidermal nerve fiber in painful neuropathies in some patients,13 the repeated skin biopsy 6 months later in our second patient revealed no reduction of fiber density. This suggests that the axonal swellings associated with nitrofurantoin may not be a harbinger to subsequent epidermal nerve fiber degeneration.

Various drugs have been implicated in neurotoxic neuropathy. More than 50 compounds including antimicrobials, antineoplastics, antiretrovirals, and cardiovascular, hypnotic, and psychotropic drugs have been implicated.12 Clinicians have to be vigilant to the possible neurotoxic effect of any medication, especially in elderly patients or those with impaired renal function. Careful neurologic examination and NCS complemented by either sural nerve biopsy or skin biopsy may help to establish the diagnosis. Referral for skin biopsy in the clinical setting of small-fiber neuropathy with normal NCS findings is helpful to confirm the diagnosis and potentially sheds light on the mechanism of injury. Early recognition of the cause and removal of the implicating drug will aid recovery and may reverse the injury. Corticosteroid may have a role,14 although the withdrawal was associated with the rebound of patients' symptoms. Nitrofurantoin may precipitate an autoimmune ganglionitis that is partially responsive to corticosteroid, as in the process implicated in nitrofurantoin-induced autoimmune hepatitis.15

In conclusion, nitrofurantoin neuropathy may present with a wide spectrum of manifestations, more commonly large-fiber sensorimotor neuropathy and small-fiber neuropathy. Non–length-dependent neuropathy/ganglionopathy is rarely described in neurotoxic neuropathy. Nitrofurantoin neuropathy has a characteristic morphology as demonstrated in these cases. Skin biopsy helps to confirm the diagnosis and plays an important role in the management of these patients.

Correspondence: Justin C. McArthur, MBBS, MD, Department of Neurology, The Johns Hopkins University School of Medicine, 600 N Wolfe St, Baltimore, MD 21287 (jm@jhmi.edu).

Accepted for Publication: July 12, 2011.

Author Contributions:Study concept and design: Tan, Polydefkis, and McArthur. Acquisition of data: Polydefkis, Hauer, and McArthur. Analysis and interpretation of data: Tan, Ebenezer, and McArthur. Drafting of the manuscript: Tan, Ebenezer, and McArthur. Critical revision of the manuscript for important intellectual content: Tan, Polydefkis, Hauer, and McArthur. Statistical analysis: Tan. Administrative, technical, and material support: Ebenezer and Hauer. Study supervision: Polydefkis, Hauer, and McArthur.

Financial Disclosure: None reported.

McCarthy BG, Hsieh ST, Stocks A,  et al.  Cutaneous innervation in sensory neuropathies: evaluation by skin biopsy.  Neurology. 1995;45(10):1848-1855
PubMed   |  Link to Article
Morris JS. Nitrofurantoin and peripheral neuropathy with megaloblastic anaemia.  J Neurol Neurosurg Psychiatry. 1966;29(3):224-228
PubMed   |  Link to Article
Sachs J, Geer T, Noell P, Kunin CM. Effect of renal function on urinary recovery of orally administered nitrofurantoin.  N Engl J Med. 1968;278(19):1032-1035
PubMed   |  Link to Article
Olivarius B. Polyneuropathy during treatment with nitrofuraixuin.  Ugeskr Laeger. 1956;118:753-755de Fine
PubMed
Yiannikas C, Pollard JD, McLeod JG. Nitrofurantoin neuropathy.  Aust N Z J Med. 1981;11(4):400-405
PubMed   |  Link to Article
Toole JF, Parrish ML. Nitrofurantoin polyneuropathy.  Neurology. 1973;23(5):554-559
PubMed   |  Link to Article
Kammire LD, Donofrio PD. Nitrofurantoin neuropathy: a forgotten adverse effect.  Obstet Gynecol. 2007;110(2, pt 2):510-512
PubMed   |  Link to Article
Mendell JR, Sahenk Z. Clinical practice: painful sensory neuropathy.  N Engl J Med. 2003;348(13):1243-1255
PubMed   |  Link to Article
Gorson KC, Herrmann DN, Thiagarajan R,  et al.  Non-length dependent small fibre neuropathy/ganglionopathy.  J Neurol Neurosurg Psychiatry. 2008;79(2):163-169
PubMed   |  Link to Article
Lauria G, Sghirlanzoni A, Lombardi R, Pareyson D. Epidermal nerve fiber density in sensory ganglionopathies: clinical and neurophysiologic correlations.  Muscle Nerve. 2001;24(8):1034-1039
PubMed   |  Link to Article
Chai J, Herrmann DN, Stanton M, Barbano RL, Logigian EL. Painful small-fiber neuropathy in Sjogren syndrome.  Neurology. 2005;65(6):925-927
PubMed   |  Link to Article
Argov Z, Mastaglia FL. Drug-induced peripheral neuropathies.  Br Med J. 1979;1(6164):663-666
PubMed   |  Link to Article
Lauria G, Morbin M, Lombardi R,  et al.  Axonal swellings predict the degeneration of epidermal nerve fibers in painful neuropathies.  Neurology. 2003;61(5):631-636
PubMed   |  Link to Article
Dabby R, Gilad R, Sadeh M, Lampl Y, Watemberg N. Acute steroid responsive small-fiber sensory neuropathy: a new entity?  J Peripher Nerv Syst. 2006;11(1):47-52
PubMed   |  Link to Article
Appleyard S, Saraswati R, Gorard DA. Autoimmune hepatitis triggered by nitrofurantoin: a case series.  J Med Case Reports. 2010;4:311
PubMed   |  Link to Article

Figures

Place holder to copy figure label and caption
Graphic Jump Location

Figure. Skin biopsy findings. A, Baseline skin biopsy specimen from the distal leg showing preserved epidermal fibers and clusters of abnormal axonal swellings in the dermis (arrows) that persisted after 6 months. Staining was done with panaxonal protein gene product 9.5 (ubiquitin hydrolase; ABD Serotec). B, The nerve fibers were immunostained with the panaxonal marker protein gene product 9.5. Scale bars indicate 50 μm.

Tables

References

McCarthy BG, Hsieh ST, Stocks A,  et al.  Cutaneous innervation in sensory neuropathies: evaluation by skin biopsy.  Neurology. 1995;45(10):1848-1855
PubMed   |  Link to Article
Morris JS. Nitrofurantoin and peripheral neuropathy with megaloblastic anaemia.  J Neurol Neurosurg Psychiatry. 1966;29(3):224-228
PubMed   |  Link to Article
Sachs J, Geer T, Noell P, Kunin CM. Effect of renal function on urinary recovery of orally administered nitrofurantoin.  N Engl J Med. 1968;278(19):1032-1035
PubMed   |  Link to Article
Olivarius B. Polyneuropathy during treatment with nitrofuraixuin.  Ugeskr Laeger. 1956;118:753-755de Fine
PubMed
Yiannikas C, Pollard JD, McLeod JG. Nitrofurantoin neuropathy.  Aust N Z J Med. 1981;11(4):400-405
PubMed   |  Link to Article
Toole JF, Parrish ML. Nitrofurantoin polyneuropathy.  Neurology. 1973;23(5):554-559
PubMed   |  Link to Article
Kammire LD, Donofrio PD. Nitrofurantoin neuropathy: a forgotten adverse effect.  Obstet Gynecol. 2007;110(2, pt 2):510-512
PubMed   |  Link to Article
Mendell JR, Sahenk Z. Clinical practice: painful sensory neuropathy.  N Engl J Med. 2003;348(13):1243-1255
PubMed   |  Link to Article
Gorson KC, Herrmann DN, Thiagarajan R,  et al.  Non-length dependent small fibre neuropathy/ganglionopathy.  J Neurol Neurosurg Psychiatry. 2008;79(2):163-169
PubMed   |  Link to Article
Lauria G, Sghirlanzoni A, Lombardi R, Pareyson D. Epidermal nerve fiber density in sensory ganglionopathies: clinical and neurophysiologic correlations.  Muscle Nerve. 2001;24(8):1034-1039
PubMed   |  Link to Article
Chai J, Herrmann DN, Stanton M, Barbano RL, Logigian EL. Painful small-fiber neuropathy in Sjogren syndrome.  Neurology. 2005;65(6):925-927
PubMed   |  Link to Article
Argov Z, Mastaglia FL. Drug-induced peripheral neuropathies.  Br Med J. 1979;1(6164):663-666
PubMed   |  Link to Article
Lauria G, Morbin M, Lombardi R,  et al.  Axonal swellings predict the degeneration of epidermal nerve fibers in painful neuropathies.  Neurology. 2003;61(5):631-636
PubMed   |  Link to Article
Dabby R, Gilad R, Sadeh M, Lampl Y, Watemberg N. Acute steroid responsive small-fiber sensory neuropathy: a new entity?  J Peripher Nerv Syst. 2006;11(1):47-52
PubMed   |  Link to Article
Appleyard S, Saraswati R, Gorard DA. Autoimmune hepatitis triggered by nitrofurantoin: a case series.  J Med Case Reports. 2010;4:311
PubMed   |  Link to Article

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics